



The Lupus Foundation of America would like to alert you about a clinical study taking place in your area.

The BLISS study (Belimumab International SLE Study) is enrolling people with lupus to test an investigational medicine that is designed to target specific proteins that have been associated with lupus. The study of belimumab is designed for people with systemic lupus (officially known as systemic lupus erythematosus, or SLE). It is being sponsored by Human Genome Sciences, which discovered and is developing belimumab.

Those eligible for the BLISS study must be:

- Age 18 or older.
- Diagnosed with systemic lupus (SLE).
- Being treated with a lupus therapy that has not changed in the past 30 days.

For more information about the study and additional eligibility criteria, visit the BLISS website at <http://www.bliss-study.com/> to find out more and to identify a doctor near you who will help determine if you are eligible.

As you may know, approximately 1.5 million Americans have some form of lupus. Ninety percent of people with lupus are women and 80% develop it between the ages of 15 and 45. It is two to three times more common among African Americans, Hispanics/Latinos, Asians and Native Americans. Unfortunately, medications for lupus are limited and no new medication has been approved in the last 40 years.

The LFA provides this information as a public service to its constituents. We do not endorse or recommend any particular clinical study. Choosing to participate in a clinical trial of a potential new treatment is an important, personal decision. You may want to consult with your physician, family or close friends before considering enrollment. You may also visit <http://www.clinicaltrials.gov/> to learn more about participating in clinical trials.